22 08 18 potentiel investors

CS MEDICA intensifies their discussion with potential investors regarding a Direct Issue, on a share price goal of 31,50 DKK

CS MEDICA A/S (“CS MEDICA” or the “Company”) need to inform the market that they aim to secure and capitalize on their first mover advantages by securing the necessary capital, hence they are intensifying their effort to close a Direct Issue, on a share price goal of 31,50 DKK with new investors.

CS MEDICA’s goal is to become a leading company in the cannabis medical treatment industry, by utilizing its first mover advantages. This status will be ensured, through accelerated growth and multiple revenue streams based on a product portfolio for autoimmune and stress-related disorders, benefiting patients and healthcare providers worldwide.

As mentioned at the webinar held on Tuesday 16/8 2022, the speed at which this can be achieved depends on the funding available. The company secured funding to maintain momentum and controlled growth through the finalized bridge loan of DKK 6 million and their TO 1 warrants. However, further funding is needed to fully capitalize on their first mover advantage and accelerate their global market expansion and product development. Hence the company intensifies their focus on finalizing a Direct Issue, with a share price goal of 31,50 DKK per share.

CS MEDICA’s current goal is to close a Direct issue of a total number of shares between 158.730 and 1.904.762, corresponding to a capital injection of 5 to 60 MDKK.
Some statements may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential distributor agreements) are forward-looking statements. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company’s ability to control or predict, which may cause the actual results of the Company to differ materially from those discussed in the forwardlooking statements.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described, there may be other factors that cause results or events not to be as anticipated, estimated or intended. The forward-looking statements included in this report are made as of the date of this press release and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.


[1] Meeting a market value of over SEK 150 million, a free float of 25%, accounting according to IFRS and follows the code for corporate governance.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.